The JoyScore Experiment.
Where Science Meets Joy and Human Connection
A global open-science project to measure joy, synchrony, and human connection — and to understand how they shape healthspan, resilience and flourishing.
For centuries, humans have gathered to dance, move, and celebrate together. Today, neuroscience is finally catching up with what culture has always known: human connection and synchrony is medicine.
The JoyScore Experiment is the research engine behind Longevity Rave — a multi-year scientific programme studying how rhythm, movement, and shared energy affect the brain, the heart, the immune system, and our long-term resilience.
We use cutting-edge tools — from mobile brain EEG tracking to cutting-edge longevity biomarkers — to understand how joy moves through a group, how it spreads, and how it transforms us.
THE SCIENCE BEHIND JOY.
Joy, belonging and social connection are strongly linked to human health, but remain difficult to quantify in biologically meaningful ways. The JoyScore Experiment is a multimodal observational framework designed to measure these experiences as components of the human ‘exposome’, the totality of environmental, social, sensory, and behavioural inputs that shape healthspan.
The framework distinguishes exposures, mediators and outcomes, and tests the hypothesis that synchrony across behavioural, cardiac and neural systems is a measurable mechanism of human connection and co-regulation.
The JoyScore experiment is a ‘social exposome’ project that sits inside the broader Human Exposome Project — it will help us build the world’s first JoyScore metric— a scientific metric for collective joy and its downstream benefits for resilience, flourishing, and health.
PILOT STUDY:
Frontier Tower (San Francisco)
4-9 December 2025
Our pilot study, Phase 0, got alot of interest. Seethe detailed piece Welcome to joyspan, the hot new trend in longevity in San Francisco Standard and Joy Gets Measured published in Longevity Technology.
We have completed Phase 1 (Honduras, February 2026). A poster informed by the findings from Phase 1 of the study is being presented at the Global Exposome Summit in April 2026 (abstract here).
In Phase 2 conducted throughout 2026, all participants will be asked to contribute core data on subjective EMA monitoring, wearable EEG, ECG, salivary biomarkers and exploratory biological anchors including metabolomic, epigenetic and glycomic measures.